NCT00629343 · OUTCOME

Maximum Tolerated Dose of Temozolomide

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide · Source last updated 2025-06-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: mg/m^2
Interval / dispersion: Not reported
Time frame: Up to 26 weeks for each dosing cohort

What was measured

Maximum tolerated dose of temozolomide when used in combination with azacitidine

Groups in this outcome

Treatment

Subjects will receive azacitidine in combination with temozolomide Azacitidine: Azacitidine will be delivered sub-cutaneously for 5 days Temozolomide: Temozolomide will be given starting on day 8 for 5 days at a dose of 200 mg/m2 po qd x 5 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment	23

Reported measurements

Source class 1

Values in mg/m^2 · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment	200	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
200

denoms

counts
group Id
OG000
value
23
units
Participants

description

Maximum tolerated dose of temozolomide when used in combination with azacitidine

groups

description
Subjects will receive azacitidine in combination with temozolomide Azacitidine: Azacitidine will be delivered sub-cutaneously for 5 days Temozolomide: Temozolomide will be given starting on day 8 for 5 days at a dose of 200 mg/m2 po qd x 5 days
id
OG000
title
Treatment

param Type

NUMBER

reporting Status

POSTED

time Frame

Up to 26 weeks for each dosing cohort

title

Maximum Tolerated Dose of Temozolomide

type

PRIMARY

unit Of Measure

mg/m^2

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice